Loading...

DCTH DELCATH SYSTEMS INC US FDA Inspections 8-K Filing

DLCT

DCTH

DELCATH SYSTEMS INC

(DCTH)

2023 8-K

Show Summary

Show Summary

Equity Offerings

Financial Statements

Accountant Change

Financial Results

Financial Results

Warrant Exercise

Financial Results

Q3 Revenue Update

Positive Study Results

Positive Study Results

Earnings Report

Employment Agreements

Compliance with Nasdaq List...

Notice of Delisting and Dep...

Earnings Reports

Agreement Extension

Earnings Reports

Securities Purchase Agreement

Appointment of Chief Operat...

Departure of Directors or C...

J-code for HEPZATO established

Presentation Availability

Earnings Report

FDA Approval of HEPZATO Kit

Earnings Reports

Disclosure of Staging Site ...

Appointment of Sandra Penne...

Earnings Reports

External Links:

Delcath Systems, Inc. announced that the FDA approved their HEPZATO Kit for the treatment of unresectable hepatic-dominant metastatic uveal melanoma.

AI Assistant

DELCATH SYSTEMS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.